Uliledlimab is a humanized anti-CD73 monoclonal antibody with antineoplastic activity. Uliledlimab inhibits adenosine generation in a non-competitive manner and suppresses tumor growth when combined with a PD-L1 inhibitor.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.